About  Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, established in 1907 and headquartered in Vadodara, Gujarat, is a research-driven integrated pharmaceutical company. It operates FDA-approved manufacturing facilities and R&D centers in Vadodara and Hyderabad, focusing on generic formulations and Active Pharmaceutical Ingredients (APIs). Its operations are structured into three verticals: Domestic Branded Business, International Generics, and APIs.

The portfolio spans therapy areas including Cardiology, Orthopaedics, Anti-Diabetic, Ophthalmology, Gynaecology, Nephrology, Gastrology, Urology, Dermatology, Anti-Infective, Cold & Cough, and Animal Health. Alembic serves 76 international markets, with exports contributing 57% of FY25 turnover. Four flagship brands crossed ₹1 billion in sales (per IPM). The company manages 204 brands, including 28 leaders, 24 ranked among the top three in their molecule group, and 73 generating over ₹10 crore revenue.

As of March 31, 2025, Alembic reports nine manufacturing facilities, 16,500+ employees, 915+ R&D personnel, and 756 cumulative filings (US 266; RoW 490).

 Alembic Pharmaceuticals Limited’s Business Segments

• Operating divisions: Domestic Branded Business, International Generics, and APIs. 
• Industries served: Pharmaceutical formulations and APIs across acute and specialty therapies, plus Animal Health. 
• Revenue by geography (FY25, consolidated): India ₹2,618.40 crore; Outside India ₹4,053.68 crore. 
• Revenue by vertical (FY25, consolidated sales including export incentives): Formulations – India Branded ₹2,339.25 crore; Formulations – International ₹3,199.95 crore; API – India ₹279.15 crore; API – International ₹853.73 crore; Total ₹6,672.08 crore. 
• Product split: Formulations ₹5,539.20 crore; API ₹1,132.88 crore (FY25).

 Alembic Pharmaceuticals Limited Key Management

• Mr. Chirayu Amin – Chairman & CEO, KMP. 
• Mr. Pranav Amin – Managing Director, KMP. 
• Mr. Shaunak Amin – Managing Director, KMP. 

Latest Updates on  Alembic Pharmaceuticals Limited

• Product launches: 16 new U.S. launches in FY25 (9 Oral Solids, 2 Injectable, 2 Ophthalmic, 3 Dermatology), driving 13% growth in U.S. generics despite price erosion. 
• Capacity expansion: FDA approval for F4 oral solids unit; 15 products shifted from F1 to F4, with more transfers planned over 24–30 months. 
• New facility: Pithampur formulation facility commissioned April 26, 2025. 
• International growth: 115 registrations filed/approved in Chile in two years; 40 products commercialized; Brazil footprint established. 
• API investments: New blocks and modernization underway to meet internal and external demand. 
• Portfolio actions: Step-down subsidiaries Okner Realty LLC and Alembic Labs LLC dissolved; TicTwo Therapeutics Inc. acquired; Alembic Life Sciences Inc. incorporated. 
• Dividend: Board recommended final dividend of ₹11 per share (550%) for FY25. 
• Credit ratings: CRISIL AA+/Stable (long-term), CRISIL A1+ and CARE A1+ (Commercial Papers) reaffirmed.